Search by drug, manufacturer, or indication

Displaying 781 - 790 of 1165

Dupixent (dupilumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Atopic dermatitis

Last updated September 17, 2019

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated September 9, 2019

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Melanoma adjuvant therapy

Last updated September 6, 2019

Alunbrig (brigatinib)

Status:

Negotiations were not pursued

Manufacturer:

Takeda Canada Inc.

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated September 5, 2019

Tafinlar/Mekinist (dabrafenib/trametinib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Melanoma adjuvant therapy

Last updated August 30, 2019

Unituxin (dinutuximab)

Status:

Concluded with an LOI

Manufacturer:

United Therapeutics

Indication:

Neuroblastoma

Last updated August 30, 2019

Zirabev (bevacizumab)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer

Last updated August 28, 2019

Monoprost (latanoprost)

Status:

Concluded without agreement

Manufacturer:

Laboratoires Thea

Indication:

Glaucoma and Ocular Hypertension

Last updated August 28, 2019

Imfinzi (durvalumab)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Non-small Cell Lung Cancer

Last updated August 26, 2019

Cystadrops (cysteamine)

Status:

Concluded with an LOI

Manufacturer:

Recordati Rare Diseases Canada Inc.

Indication:

Corneal cystine crystal deposits

Last updated August 22, 2019